Management of Bilateral Medullary Nephrocalcinosis
Diagnostic Workup
- The National Kidney Foundation recommends a comprehensive metabolic evaluation to determine the underlying etiology of bilateral medullary nephrocalcinosis, including serum electrolytes, acid-base status, renin, aldosterone, and creatinine 1, 2
- The American Society of Nephrology suggests assessing for hypercalciuria using the urinary calcium-creatinine ratio 1, 2
- The European Renal Association recommends renal ultrasound as the primary modality to detect medullary nephrocalcinosis 1, 2
- The International Society of Nephrology advises reserving CT scanning for cases requiring precise localization of obstructive stones, given radiation burden 1, 3
- Genetic testing is recommended to confirm clinical diagnosis with genetic analysis when Bartter syndrome or other hereditary tubulopathies are suspected (grade B recommendation) 1, 3
Treatment Approach by Etiology
- The American Academy of Pediatrics recommends sodium chloride supplementation adjusted individually based on severity, age, and GFR for Bartter syndrome with nephrocalcinosis 4, 5, 6
- The National Institute of Diabetes and Digestive and Kidney Diseases suggests potassium chloride supplementation for hypokalemia in Bartter syndrome with nephrocalcinosis 4, 5, 6
- The American College of Medical Genetics recommends NSAIDs (indomethacin) as mainstay therapy, particularly during early years of life, for Bartter syndrome with nephrocalcinosis 4, 5, 6, 7
- The European Society of Pediatric Nephrology advises high fluid intake to maintain adequate hydration for Bartter syndrome with nephrocalcinosis 4
Monitoring Protocol
- The American Society of Nephrology recommends stopping therapy immediately if hyperkalemia develops, significant rise in serum creatinine occurs, or significant fall in hemoglobin or hematocrit is observed 1